University of Pennsylvania

ScholarlyCommons
Departmental Papers (Dental)

Penn Dental Medicine

9-17-2004

Uncoupling of Photoreceptor Peripherin/rds Fusogenic Activity
from Biosynthesis, Subunit Assembly, and Targeting A
POTENTIAL MECHANISM FOR PATHOGENIC EFFECTS*
Linda M. Ritter
Nidhi Khattree
Shu-Chu Chen
Andrew F.X. Goldberg
Kathleen Boesze-Battaglia
University of Pennsylvania

See next page for additional authors

Follow this and additional works at: https://repository.upenn.edu/dental_papers
Part of the Dentistry Commons

Recommended Citation
Ritter, L. M., Khattree, N., Chen, S., Goldberg, A. F., Boesze-Battaglia, K., Tam, B. M., & Moritz, O. L. (2004).
Uncoupling of Photoreceptor Peripherin/rds Fusogenic Activity from Biosynthesis, Subunit Assembly, and
Targeting A POTENTIAL MECHANISM FOR PATHOGENIC EFFECTS*. Journal of Biological Chemistry, 279
(38), 39958-39967. http://dx.doi.org/10.1074/jbc.M403943200

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_papers/251
For more information, please contact repository@pobox.upenn.edu.

Uncoupling of Photoreceptor Peripherin/rds Fusogenic Activity from
Biosynthesis, Subunit Assembly, and Targeting A POTENTIAL MECHANISM FOR
PATHOGENIC EFFECTS*
Abstract
Inherited defects in the RDS gene cause a multiplicity of progressive retinal diseases in humans. The gene
product, peripherin/rds (P/rds), is a member of the tetraspanin protein family required for normal
vertebrate photoreceptor outer segment (OS) architecture. Although its molecular function remains
uncertain, P/rds has been suggested to catalyze membrane fusion events required for the OS renewal
process. This study investigates the importance of two charged residues within a predicted C-terminal
helical region for protein biosynthesis, localization, and interaction with model membranes. Targeted
mutagenesis was utilized to neutralize charges at Glu321 and Lys324 individually and in combination to
generate three mutant variants. Studies were conducted on variants expressed as 1) full-length P/rds in
COS-1 cells, 2) glutathione S-transferase fusion proteins in Escherichia coli, and 3) membrane-associated
green fluorescent protein fusion proteins in transgenic Xenopus laevis. None of the mutations affected
biosynthesis of full-length P/rds in COS-1 cells as assessed by Western blotting, sedimentation velocity,
and immunofluorescence microscopy. Although all mutations reside within a recently identified
localization signal, none altered the ability of this region to direct OS targeting in transgenic X. laevis
retinas. In contrast, individual or simultaneous neutralization of the charged amino acids Glu321 and
Lys324 abolished the ability of the C-terminal domain to promote model membrane fusion as assayed by
lipid mixing. These results demonstrate that, although overlapping, C-terminal determinants responsible
for OS targeting and fusogenicity are separable and that fusogenic activity has been uncoupled from
other protein properties. The observation that subunit assembly and OS targeting can both proceed
normally in the absence of fusogenic activity suggests that properly assembled and targeted yet
functionally altered proteins could potentially generate pathogenic effects within the vertebrate
photoreceptor.
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Inherited defects in the RDS gene cause a multiplicity of progressive retinal diseases in humans. The
gene product, peripherin/rds (P/rds), is a member of the tetraspanin protein family required for normal
vertebrate photoreceptor outer segment (OS) architecture. Although its molecular function remains
uncertain, P/rds has been suggested to catalyze membrane fusion events required for the OS renewal
process. This study investigates the importance of two charged residues within a predicted C-terminal
helical region for protein biosynthesis, localization, and interaction with model membranes. Targeted
mutagenesis was utilized to neutralize charges at Glu321 and Lys324 individually and in combination
to generate three mutant variants. Studies were conducted on variants expressed as 1) full-length P/
rds in COS-1 cells, 2) glutathione S-transferase fusion proteins in Escherichia coli, and 3) membraneassociated green fluorescent protein fusion proteins in transgenic Xenopus laevis. None of the
mutations affected biosynthesis of full-length P/rds in COS-1 cells as assessed by Western blotting,
sedimentation velocity, and immunofluorescence microscopy. Although all mutations reside within
a recently identified localization signal, none altered the ability of this region to direct OS targeting
in transgenic X. laevis retinas. In contrast, individual or simultaneous neutralization of the charged
amino acids Glu321 and Lys324 abolished the ability of the C-terminal domain to promote model
membrane fusion as assayed by lipid mixing. These results demonstrate that, although overlapping,
C-terminal determinants responsible for OS targeting and fusogenicity are separable and that
fusogenic activity has been uncoupled from other protein properties. The observation that subunit
assembly and OS targeting can both proceed normally in the absence of fusogenic activity suggests
that properly assembled and targeted yet functionally altered proteins could potentially generate
pathogenic effects within the vertebrate photoreceptor.
1

Rod and cone vertebrate photoreceptor outer segments (OSs) contain hundreds of neatly
stacked photopigment-containing membranous disks that are essential for normal vision. A
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polarized renewal process replaces these membranes such that a complete turnover of OS disks
in rod cells is effected approximately once every 10 days (1). Renewal is thought necessary to
counter the effects of light damage and oxidation of OS lipids, and evidence from several
laboratories has shown that a coordination of new disk assembly (morphogenesis) with aged
disk removal (shedding) is needed to maintain normal OS structure (2,3). Defects in disk
morphogenesis or shedding that compromise the renewal process lead to disorganization of
the OS layer and eventual photoreceptor cell death. Although OS renewal has been linked to
environmental factors including light, temperature, and ionic milieu, the process is not
currently well understood in molecular terms, particularly with regard to regulation of the
membrane fusion processes required (2).
The rds (retinal degeneration slow) gene product, peripherin/rds (P/rds; also known as
photoreceptor peripherin, peripherin/rds, rds/peripherin, rds, and peripherin-2), appears to be
a central player in OS morphogenesis and the renewal process. First described in 1978, the
rds mouse possesses a large insertion of viral DNA in chromosome 17 that results in a null
allele (4-6). Heterozygous and homozygous animals display irregular and absent OSs,
respectively, with otherwise normal retinal morphology at young ages (7,8). Photoreceptor cell
bodies subsequently die by apoptosis, and deterioration of the photoreceptor cell layer in
homozygotes is essentially complete by 12 months of age (9,10).
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1The abbreviations used are:
OS
outer segment
P/rds
peripherin/rds
EC2
extracellular/intradiskal loop 2
CHR
C-terminal helical region
GST
glutathione S-transferase
GFP
green fluorescent protein
WT
wild-type
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mAb
monoclonal antibody
FRET
fluorescence resonance energy transfer
NBD-PE
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)phosphatidylethanolamine
Rh-PE
N-(lissamine rhodamine B sulfonyl)phosphatidylethanolamine
LUVs
large unilamellar liposomes
diS-C3-(5)
3,3′-dipropylthiadicarbocyanine iodide
SUVs
small unilamellar vesicles
J Biol Chem. Author manuscript; available in PMC 2006 February 2.
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Although clearly required for OS formation, the P/rds mechanism of action at the molecular
level is less obvious. Studies from several laboratories concur that it is an integral membrane
protein localized to the rim regions of photoreceptor disks in normal retina (11,12). Present in
all vertebrate rod and cone photoreceptors examined to date, this protein causes a variety of
progressive retinal diseases in humans when defective (13). Proposals for function include disk
rim formation, disk flattening, disk stack scaffolding, disk-plasma membrane interaction, and/
or catalysis of disk renewal (14-20). Compelling evidence to favor one clearly defined mode
of action at the molecular level is still lacking. In some species, P/rds action can be modulated
by the presence of the homologous rom-1 polypeptide; however, the molecular function of
rom-1 is also unclear (21). A recent report describing the presence of a localization signal in
the C terminus of P/rds (but not rom-1) suggests a rationale for why rom-1 knockout mice can
elaborate photoreceptor OSs, but P/rds null mice cannot (20).
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We have previously used targeted mutagenesis to investigate P/rds structure-function
relationships and to show that folding and tetrameric subunit assembly are guided by discrete
determinants within the extracellular/intradiskal loop 2 (EC2) domain (22). The vast majority
of the predicted extramembranous polypeptide sequence, including a 66-amino acid C-terminal
domain, makes no measurable contribution to protein biosynthesis. In contrast, several
biophysical studies suggest that the P/rds C terminus functions to catalyze membranemembrane fusion events (17,23-25). Those studies indicate that the C terminus contains an
amphipathic helix that functions as a fusion peptide, and a recent investigation found that
truncating the protein within the helix greatly diminishes fusogenic activity (25).
Fusion peptides are short amphiphilic helical regions essential for the activity of known
membrane fusion proteins (26,27). Their amphiphilic character is thought to promote
membrane destabilization via insertion into and disruption of bilayer structures; however,
mechanisms of fusion peptide action are still being widely debated and studied (27). Likewise,
amphiphilicity appears to be important for the proposed P/rds fusion peptide; the membrane
destabilization activity of a P/rds synthetic peptide model was strongly inhibited when its
amphiphilicity was reduced by decreasing hydrophobicity (24). It is noteworthy that rom-1, a
peripherin/rds homolog, lacks strong amphiphilicity in this region and is unable to promote
membrane fusion in vitro (28). In particular, rom-1 possesses non-polar substitutions at two
positions relative to the conserved P/rds fusion peptide sequence that result in a loss of two
charged residues (Glu321 and Lys324) and a decrease in predicted hydrophobic moment. The
significance of charged residues in the P/rds fusion peptide has not been examined to date,
although ionizable amino acids are reported to play an important role in several other fusion
peptides (27,29).
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An improved understanding of P/rds C-terminal structure-function relationships is required to
relate fusogenic activity measured in vitro to its proposed molecular function in the
photoreceptor OS. This is an inherently difficult undertaking, as there are no facile approaches
to assay the membrane fusion events involved in the vertebrate photoreceptor renewal process.
This task is complicated by the recent identification of a C-terminal OS localization signal that
overlaps the previously identified fusion peptide (20). This study examines the significance of
two conserved charged residues, Glu321 and Lys324, to further our understanding of how the
C-terminal domain contributes to P/rds function. We find that these residues are essential for
P/rds fusogenic activity, but not biosynthesis, subunit assembly, or OS localization. The
uncoupling of fusogenic activity from other properties suggests that properly assembled and
targeted yet functionally altered proteins could generate pathogenic effects in the vertebrate
photoreceptor.
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Engineering C-terminal Helical Region (CHR) Mutants for Expression in COS-1 Cells,
Escherichia coli, and Xenopus laevis—Three sets of constructs were used in this study (see
Fig. 1C). The first set encodes full-length (346 predicted amino acids) bovine P/rds for
expression in COS-1 cells and was used for the assay of protein biosynthesis and subunit
assembly. The second set of constructs, encoding only the 66-amino acid P/rds C-terminal
domain fused to glutathione S-transferase (GST), was used to express and purify proteins from
E. coli and was used for assay of membrane interactions. Lack of cell-surface expression in
COS-1 cells precluded the routine use of full-length mutants for membrane interaction studies.
The third set of constructs, encoding the 66-amino acid P/rds C-terminal domain fused to green
fluorescent protein (GFP), was utilized to drive protein expression in transgenic X. laevis for
the assay of subcellular localization. Each set of constructs includes wild-type (WT) P/rds and
three variants, two single missense mutations (E321L and K324A) and the combined double
missense mutation (E321L,K324A).

NIH-PA Author Manuscript

The bacterial expression plasmids were based upon pGST-CTER, an inducible expression
vector encoding GST followed by the 66-amino acid hydrophilic C terminus of WT bovine P/
rds (25). Nucleotide base changes were designed to introduce point mutations into the
previously identified fusion peptide region Val312-Leu326 (17,24). In each instance, a charged
residue conserved across P/rds orthologs was replaced by an uncharged residue from the
homologous region of the aligned bovine rom-1 sequence (see Fig. 1B). Single and double
mutants were constructed serially using synthetic oligonucleotide primers (Table I) and the
QuikChange site-directed mutagenesis kit (Stratagene). Mutagenized regions were verified by
DNA sequencing using a BigDye terminator cycle sequencing kit (Applied Biosystems, Inc.).
Mutagenized regions (as BamHI fragments) were returned to non-mutagenized expression
vector backgrounds by subcloning to generate bacterial expression plasmids pGST-E321L,
pGST-K324A, and pGST-E321L,K324A. Correct assembly of the plasmids was confirmed by
restriction mapping.
The mammalian expression plasmids were based upon the bacterial expression series described
above and a cDNA clone encoding the full-length WT P/rds sequence (30,31). A 157-bp StuI/
BamHI fragment containing the mutagenized CHR was excised from each variant and
subcloned into the StuI/BamHI-digested subcloning vector pScXho (32). The mutagenized
CHRs were then excised as SacII/XhoI fragments and ligated into SacII/XhoI-digested
pcPERS, the non-mutagenized expression vector background containing the full-length protein
coding region of bovine P/rds (22). Completed constructs were confirmed by restriction
mapping.
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The constructs designed for expression of mutant variants in transgenic X. laevis were based
on the plasmid pEGFP-C1 (Clontech). The cytomegalovirus promoter was replaced with a 0.8kb fragment of the proximal X. laevis opsin promoter (pXOP-0.8). Following the GFP cDNA,
a sequence encoding the C terminus of X. laevis rhodopsin lacking the terminal five amino
acids (i.e. amino acids 311-348) was inserted to create pXOP-0.8-EGFP-rhoCT. This plasmid
was designed to accept the BamHI fragments encoding the 66 amino acids of bovine P/rds
(described above) in-frame behind the GFP-rhodopsin sequence. The presence of a
palmitoylation signal within the rhodopsin sequence creates a membrane-bound GFP reporter
molecule (20). The desired constructs were selected and verified by restriction mapping. The
previously described constructs GFP-rhoCT44 and GFP-rhoCT44del5 were also used as
controls (33).
Assay of Expression and Disulfide Bonding in COS-1 Cells—P/rds-containing membranes
were prepared at 4 °C from transiently transfected COS-1 cells as follows. Adherent cells grown
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on 100-mm plastic culture dishes were washed three times with Tris-buffered saline 48 h posttransfection. Cells were scraped from plates with a rubber policeman and collected into 1 ml
of Tris-buffered saline containing 2.5 mM N-ethylmaleimide, 1 μg/ml leupeptin, 1 μg/ml
pepstatin A, and 5 μg/ml Pefabloc-SC (Roche Applied Science). The cells were pelleted by
centrifugation at 2000 × g for 10 min at 4 °C. The cell pellets were resuspended in 1.2 ml of
10 mM Tris-HCl (pH 7.5) containing 2.5 mM N-ethylmaleimide, 1 μg/ml leupeptin, 1 μg/ml
pepstatin A, and 5 μg/ml Pefabloc-SC. The resuspended cells were passed forcefully through
26-gauge syringe needles five times, and the resulting lysates were centrifuged at 1000 × g for
10 min at room temperature. Supernatants were transferred to ultracentrifuge tubes and
centrifuged at 110,000 × g for 20 min at 4 °C. The membrane pellets were resuspended by
vortexing and trituration in 115-μl aliquots of Tris-buffered saline containing 2.5 mM Nethylmaleimide, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, and 5 μg/ml Pefabloc-SC. COS-1 cell
membranes prepared in this fashion were stored at -70 °C until used.
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Western blot analysis of WT and mutant P/rds expression and disulfide bonding in transfected
COS-1 membranes was performed using anti-P/rds monoclonal antibody (mAb) C6 and
methods described previously (22). Thawed COS-1 cell membranes (3 μl/lane) were
solubilized with denaturing sample buffer containing 5% β-mercaptoethanol, and samples were
heated in boiling water for 5 min prior to loading onto 10% SDS-polyacrylamide gels. Analysis
of disulfide bonding was performed in an analogous manner in the absence of βmercaptoethanol.
Immunofluorescent Localization in COS-1 Cells—WT and mutant P/rds were localized in
transiently transfected COS-1 cells as described previously (22). In brief, paraformaldehydefixed cells were permeabilized with Triton X-100 and then processed using anti-P/rds mAb C6
and a secondary anti-mouse IgG antibody covalently labeled with the Cy3 fluorophore
(Amersham Biosciences). A similar procedure used a 1:200 dilution of a mouse anti-KDEL
receptor monoclonal antibody (Stressgen Biotech Corp.) in conjunction with a secondary antimouse IgG antibody covalently labeled with the Cy2 fluorophore (Amersham Biosciences) to
label cis-Golgi and intermediate Golgi membranes. Likewise, a 1:200 dilution of a rabbit anticalnexin polyclonal antibody (Stressgen Biotech Corp.) was used in conjunction with a
secondary anti-rabbit IgG antibody covalently labeled with the Cy2 fluorophore to label the
endoplasmic reticulum. A Nikon Optiphot-2 microscope equipped with an epifluorescent
illuminator and a SPOT RT digital imaging system (Version 3.0 software, Diagnostic
Instruments Inc.) were utilized for image acquisition. Image processing was limited to
adjustment of brightness and contrast.
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Assay of Subunit Assembly by Velocity Sedimentation—A previously established procedure
was used to measure the sedimentation velocities of detergent-solubilized WT and mutant P/
rds; a Beckman Optima TLX centrifuge and TLS-55 rotor were utilized as described previously
(34). In brief, Triton X-100 extracts of transiently transfected COS-1 cells were layered onto
2-ml 5-20% sucrose gradients and centrifuged overnight at 4 °C. Soluble fractions were
collected by off-center puncture of tube bottoms; particulate fractions were collected by
solubilization of pellets with Laemmli sample buffer. Scion Image software was utilized for
image analysis of chemiluminescent Western blots; pixel summation over soluble and
particulate fractions was used to calculate total P/rds reactivity (22). Peak immunoreactivities
were taken for the calculation of s20,w values.
Mutant Expression and Subcellular Localization in Transgenic X. laevis Retina—Transgenic
tadpoles were generated using a modified protocol (36) based on that of Kroll and Amaya
(35). WT X. laevis adults were obtained from Xenopus I (Dexter, MI). X. laevis sperm nuclei
were incubated with 0.3× high speed egg extract, 0.05 units of NotI restriction enzyme, and
100-200 ng of NotI-linearized vector DNA in a total volume of 18 μl. After 10 min, the reaction
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mixture was diluted to 0.3 nuclei/nl, and 10 nl was injected per egg. The resulting embryos
were reared in 0.1× Marc’s modified Ringer’s solution containing 6% Ficoll and 50 μg/ml
gentamycin for 48 h and then transferred to 0.1× Gerhart’s modified Ringer’s solution (37).
Animals were treated with 18 μg/ml G418 for 96 h as previously described to select for
transgenic animals and to reduce the extent of gene silencing (38). At 5-6 days post-fertilization,
roughly corresponding to stages 40-42, tadpoles were screened for GFP expression using a
Zeiss Axioskop equipped with epifluorescence optics and a GFP filter set (39). Tadpoles
expressing GFP were identified by green fluorescence emitted from their eyes. All animals
were raised at 18 °C on a 12/12 light cycle (8 a.m. to 8 p.m.).
Stage 48-62 transgenic tadpoles were killed between 4 and 7 p.m. (i.e. near the end of the light
cycle) and fixed in 4% paraformaldehyde and 0.1 M sodium phosphate (pH 7.4). Fixed eyes
were embedded in OCT tissue embedding medium (Tissue-Tek) and cryosectioned. Frozen
sections (14 μm) were stained with Texas Red-conjugated wheat germ agglutinin (Molecular
Probes, Inc., Eugene, OR) and Hoechst 33342 (Sigma) to label Golgi/post-Golgi membranes
and nuclei, respectively, as previously described (20). Labeled sections were mounted in 50%
glycerol. A Zeiss LSM 510 laser scanning confocal microscope equipped with a C-Apochromat
(40× W Korr, 1.2-numerical aperture objective) and Zeiss LSM software were used to acquire
images of labeled sections. At least three transgenic animals were examined by confocal
microscopy for each construct.
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Expression and Purification of GST-C-terminal Domain Fusion Proteins—A standardized
expression and purification procedure based on methods developed for pGST-CTER was used.
Thirty ml of a plasmid-transformed, freshly saturated E. coli XL1-Blue culture was used to
inoculate 900 ml of Luria broth containing 100 μg/ml ampicillin. The culture was grown with
agitation at 37 °C for 1.5 h, and fusion protein expression was induced for an additional 3 h
(with agitation at 37 °C) by the introduction of 0.1 mM isopropyl-1-thio-β-D-galactopyranoside.
Cells were collected by centrifugation and stored at -70 °C until used.
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The frozen cell pellet was thawed on ice and resuspended by vortexing in 35 ml of ice-cold
phosphate-buffered saline (pH 7.5) containing 1 mM dithiothreitol, 1 μg/ml leupeptin, 1 μg/ml
pepstatin A, and 1 mM phenylmethylsulfonyl fluoride. The cells were lysed using a French
pressure cell, and Triton X-100 was added to a final concentration of 1%. The lysate was stirred
for 20 min at 4 °C and then centrifuged at 14,000 × g for 30 min at 4 °C. The clarified supernatant
was applied to a 6-ml column of packed glutathione-Sepharose 4B (Amersham Biosciences),
and the column was washed with 10 bed volumes of phosphate-buffered saline. The GST-Cterminal domain fusion protein was eluted by three sequential single bed volume equilibrations
of 5 min each using 50 mM Tris-HCl (pH 8.8) containing 10 mM reduced glutathione and 1
mM dithiothreitol. Combined eluates were concentrated with a stirred ultrafiltration cell;
dialyzed at 4 °C against 50 mM Tris-HCl (pH 7.0), 150 mM NaCl, 1 mM EDTA, and 1 mM
dithiothreitol; and stored in aliquots at -80 °C. Protein determinations were carried out with a
BCA assay kit (Pierce) using bovine serum albumin to construct the standard curve.
Assay of Vesicle Fusion by Lipid Mixing—An established procedure was adapted to measure
lipid mixing using fluorescence resonance energy transfer (FRET) (40). This assay is based on
the dilution of a resonance energy transfer pair, N-(7-nitro-2,1,3-benzoxadiazol-4-yl)
phosphatidylethanolamine (NBD-PE) and N-(lissamine rhodamine B sulfonyl)
phosphatidylethanolamine (Rh-PE) (Molecular Probes, Inc.), due to vesicle hemifusion and
subsequent NBD-PE dequenching. Large unilamellar vesicles (LUVs) were prepared from
phosphatidylcholine/phosphatidylserine/cholesterol (4:4:1; Avanti Polar Lipids Inc.,
Birmingham, AL) by extrusion through a 0.1-μm filter essentially as described by Mayer et
al. (41). LUVs containing 0.6 mol % Rh-PE and 0.6 mol % NBD-PE were mixed at a 1:1 molar
ratio with an unlabeled (but otherwise identical) population of LUVs (10 μM phospholipid final
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concentration) and a purified mutant variant (8.3 μg/ml final protein concentration). The
rhodamine excitation wavelength was set at 465 nm; NBD fluorescence emission was measured
at 530 nm; and a 515-nm cutoff filter was used between the sample and the emission
monochromator to decrease interference from light scattering. Under these conditions, vesicle
hemifusion results in probe dilution and a linear increase in NBD-PE fluorescence (40). FRET
was measured after 10 min (its maximal value); percent FRET was calculated as described
previously (25). No above base-line changes were observed for additions of purified GST alone
(8.3 μg of protein/mg of total lipid).
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Assay of Membrane Destabilization by Vesicle Depolarization—Membrane bilayer
destabilization was inferred from membrane depolarization studies and measured
fluorometrically with the cation-sensitive dye 3,3′-dipropylthiadicarbocyanine iodide (diSC3-(5); Molecular Probes, Inc.) as a collapse in a valinomycin-induced diffusion potential.
Small unilamellar vesicles (SUVs) were prepared by sonication from phosphatidylcholine/
phosphatidylserine/cholesterol at a 4:4:1 molar ratio in the presence of 100 mM K+ and then
diluted into K+-free isotonic buffer (3.6 μM phospholipid final concentration). The fluorescent
probe diS-C3-(5) was added to 1 nM and allowed to equilibrate at 37 °C until a stable base-line
fluorescence (λex = 620 nm and λem = 670 nm) was established. The K+ ionophore valinomycin
was added to 0.1 mM to create an inside negative electrochemical potential that resulted in diSC3-(5) quenching. Purified GST fusion proteins (10 μg/ml protein final concentration) were
assayed individually for their ability to induce SUV leakiness and to dissipate the diffusion
potential as measured by diS-C3-(5) fluorescence recovery. A similar concentration of purified
GST had no effect on fluorescence recovery. Percent fluorescence recoveries were calculated
as described (42).

RESULTS
Design and Construction of CHR Mutants—We have shown previously that defects in P/rds
can cause discrete and local as well as global disruptions of protein structure (22,32,43). Most
recently, an insertion mutagenesis approach demonstrated that, although the vast majority of
extramembranous polypeptide sequence makes no measurable contribution to gross protein
folding or tetramerization, discrete regions within the EC2 domain do include determinants
required for normal subunit assembly (22). That study aimed to identify regions making
specific local contributions; therefore, mutations were inserted outside the boundaries of
strongly predicted secondary structures, including an α-helix in the C terminus that promotes
2
model membrane fusion (17). In this study, we examined whether targeted point mutations
within the CHR affect known structural and/or functional properties of P/rds.

NIH-PA Author Manuscript

Seventeen highly conserved C-terminal amino acids (Val312-Lys328), including a minimal
region (Val312-Leu326) previously shown to adopt a helical structure and to promote model
membrane fusion (17,24), are shown in Fig. 1B. The alternation of charged (boxed) and
relatively hydrophobic residues with a three- to four-residue periodicity predicts a highly
amphipathic structure, characteristic of a membrane-binding helix. In contrast, rom-1 lacks
both this motif and fusogenic activity (28). Since two charged residues (Glu321 and Lys324)
are missing from rom-1, we wondered whether these charges are important for P/rds fusogenic
activity. We also asked whether these charges are necessary for OS localization of P/rds, given
the presence of a subcellular localization signal within this same region (20).
To test these hypotheses, we constructed a set of potentially non-fusogenic P/rds variants by
targeted mutagenesis of the CHR (Fig. 1B). Charged amino acid residues at two positions
(Glu321 and Lys324) were substituted individually and in combination with the corresponding
2Fusion is defined operationally as lipid mixing in this study. No distinction is drawn or intended between hemifusion and bona fide fusion.
J Biol Chem. Author manuscript; available in PMC 2006 February 2.
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uncharged residues found in the aligned bovine rom-1 sequence. None of the mutant variants
are predicted (using the NNPREDICT algorithm) to possess significantly altered α-helical
character (44). Mutants were expressed as full-length (polytopic) proteins in COS-1 cells, as
GST-C-terminal domain fusions in E. coli, and as C-terminal domain fusions with membraneassociated GFP in transgenic X. laevis photoreceptors (Fig. 1C).
Heterologous Expression and Disulfide Bonding of CHR Mutants in COS-1 Cells—Each of
the full-length variants was individually transfected into COS-1 cells in culture, and protein
expression was assessed by Western blot analysis using anti-P/rds mAb C6. This reagent
recognizes an epitope at the distal C terminus and is therefore a good diagnostic measure of
full-length protein expression (22). The mutagenized CHR lies ∼21 amino acids upstream of
this epitope, and mutations do not appear to affect antibody binding. All mutants expressed
robustly; the Western blot analysis shown in Fig. 2 (left panel) demonstrates that, under
denaturing and reducing conditions, all mutants possessed apparent molecular masses
comparable with that of WT P/rds.
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Mutant protein mobility was also characterized by Western analysis in the absence of added
reducing agent. It is well established that WT P/rds adopts a disulfide-bonded dimeric form
both in vertebrate retina and in COS-1 cells (15,30,31). Several examples of human retinal
disease likely involve protein misfolding as a consequence of abnormal disulfide bonding
(45-48). All three C-terminal domain mutants displayed essentially WT behavior (Fig. 2, right
panel); all migrated as both monomeric and (disulfide-bonded) dimeric forms. In sum, the data
presented demonstrate that none of the C-terminal domain mutations measurably affect normal
expression or disulfide bonding of P/rds in COS-1 cells.
Immunofluorescent Localization of CHR Mutants in COS-1 Cells—Immunofluorescence
microscopy was used to examine whether neutralization of charged residues in the CHR affects
subcellular localization of full-length P/rds variants expressed in transiently transfected
cultured cells. Properly assembled WT P/rds displays a largely perinuclear distribution in
COS-1 cells, suggesting that it remains associated with Golgi membranes; in contrast, grossly
misfolded P/rds is retained within the endoplasmic reticulum (22). A recent demonstration that
a targeting signal is encoded within the P/rds C terminus (20) prompted us to examine whether
mutations in the CHR affect targeting in transfected COS-1 cells.
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Indirect immunofluorescence was used to analyze the subcellular distribution of CHR mutants
in fixed and permeabilized COS-1 cells. All CHR mutants appeared to be essentially
indistinguishable from WT P/rds; we were unable to discern any effects of the mutations on
protein distributions. Fluorescence distributions were somewhat heterogeneous between
individual cells; images presented are representative of the most common localization patterns.
Reference images of endoplasmic reticulum and Golgi immunofluorescence labeling patterns
are shown for comparison, as is the distribution of grossly misfolded P/rds (Fig. 3A). The
subcellular distribution of WT P/rds is also shown in Fig. 3B; the protein displayed a largely
Golgi distribution, appearing as a small cap over nuclei of transfected cells. These results
demonstrate that subcellular localization patterns of P/rds are not significantly altered by
mutations that neutralize conserved CHR residues.
Subunit Assembly of CHR Mutants Expressed in COS-1 Cells—Point mutations that prevent
the normal formation of tetrameric P/rds cause progressive retinal disease in humans and
dysmorphic OSs in transgenic mice (34,43,49). We recently established a primary role for EC2
in this process and showed that discrete determinants within the EC2 domain guide tetramer
formation (22). Although no ill effects of C-terminal domain insertion mutations on subunit
assembly were found, none of the insertions disrupted the CHR directly. Therefore, we have
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examined whether the neutralization of charged residues in the CHR can affect tetrameric
assembly of P/rds.
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Subunit stoichiometry was assessed using a velocity sedimentation technique developed
previously (31). Full-length WT and mutant P/rds were expressed by transient transfection of
COS-1 in culture; the cells were extracted with Triton X-100 under nondenaturing conditions;
lysates were applied to sucrose gradients; and the gradients were centrifuged overnight.
Fractionated gradients were assayed by Western blot analysis to determine protein mobility
and to calculate sedimentation coefficients. Comparison of the mobility of a given mutant
relative to that of WT P/rds was used to assess tetrameric assembly. Fig. 4 illustrates typical
sedimentation profiles obtained for WT and mutant P/rds. In each case, greater than half of the
P/rds reactivity remained in the soluble (versus particulate) fraction. Thus, these mutations do
not cause extensive protein misfolding. In addition, the mobility of each variant is most
consistent with tetrameric stoichiometry; sedimentation coefficients, calculated from
immunoreactivity peaks, are presented in Table II. The results demonstrate that none of the
CHR mutations significantly affected gross folding or subunit assembly of full-length P/rds in
COS-1 cells.
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Targeting and Localization in Transgenic X. laevis Rod Photoreceptors—We utilized a
recently developed confocal fluorescence assay to investigate whether the mutations we
introduced into the CHR affect the ability of the C terminus of bovine P/rds to direct
photoreceptor OS targeting and localization (20). This approach uses an X. laevis opsin
promoter to drive expression of a membrane-associated GFP reporter fused to C-terminal
domain variants of bovine P/rds in transgenic X. laevis rod photoreceptors (33,38). When the
WT bovine P/rds C terminus is fused to the GFP reporter, nearly all fluorescence retargets to
the OS, the normal location of full-length endogenous P/rds. Importantly, the fluorescent
reporter does not form complexes with full-length P/rds (20). The combined results indicate
the presence of a localization signal in the P/rds C terminus that does not require other protein
domains for targeting. Analysis of mutant targeting requires the use of a P/rds fragment since
transgenic expression of full-length P/rds mutants would most likely result in co-assembly with
the high background of endogenous P/rds and masking of potential targeting defects (22,31,
38,50).
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Fig. 5 (A-C) shows typical localization patterns observed for the WT bovine sequence and the
single mutant E321L and the double mutant E321L,K324A. As described previously (20) and
as shown in Fig. 5A, the WT bovine P/rds C terminus directed the vast majority of membraneassociated GFP to the rod photoreceptor OS; only very minor amounts of GFP fluorescence
are detectable in other regions (20). This distribution is similar to that generated by the WT X.
laevis rhodopsin C terminus (Fig. 5D), the first OS localization signal identified (33). The
subcellular distributions of the mutant P/rds variants were essentially indistinguishable from
that of WT P/rds; no effect of these mutations on the ability of the C-terminal domain to direct
OS localization was observed (Fig. 5, A-C). In contrast and for the sake of comparison, Fig.
5E shows the appearance of membrane-associated GFP lacking an OS localization signal. As
reported previously (33), disruption of the X. laevis rhodopsin localization signal (by
truncation) results in broader distributions that include both lateral plasma membranes and
internal membranes of the inner segment and a clear presence in outer plexiform layer
membranes. The K324A single mutant was not assayed directly; but given the lack of effect
seen for the double mutant (Fig. 5C), it is likely that K324A would also have no disruptive
effect.
In Vitro Fusogenicity of CHR Mutants Expressed as GST Fusion Proteins in E. coli—We
adapted a FRET approach to investigate whether charged residues in the CHR are important
for P/rds fusogenic activity in vitro. Previous studies have shown that the P/rds C terminus,
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and more specifically, the CHR, can promote membrane vesicle fusion and that controlled
trypsinolysis (or genetic truncation) results in loss of fusogenic activity (17,24). Importantly,
the homologous bovine rom-1 polypeptide sequence lacks several charged residues in this
region (Fig. 1B) and does not show fusogenic activity in vitro (25). We hypothesized that
neutralizing these charged residues with neutral residues present in rom-1 would inhibit P/rds
ability to promote model membrane fusion. Fusogenicity was assayed using purified bacterially
expressed proteins, as a lack of cell-surface expression of P/rds in COS-1 adversely affected
3
signal-to-noise ratios in assays using COS-1 membranes.
Each of the variants was expressed as a GST fusion protein and subsequently purified by
affinity chromatography. The appearance of each relative to the GST-tagged WT P/rds C
terminus (GST-WT) and GST alone is shown in Fig. 6 by Coomassie Blue staining. Each
variant (including WT P/rds) ran with an apparent molecular mass of ∼28 kDa, near that of the
combined predicted masses of ∼22 and ∼6 kDa of GST and the P/rds C terminus, respectively.
Each preparation also contained several species of greater mobility, most likely truncation
products. In each case, at least 70% of the total protein was judged to be full-length.
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LUVs containing Rh-PE and NBD-PE were mixed at a 1:1 molar ratio with unlabeled LUVs
(100 nM phospholipid final concentration). Fig. 7A shows how NBD-PE fluorescence intensity
changed upon addition of the purified GST-C-terminal domain proteins. Consistent with a
previous report (25), GST-WT promoted LUV fusion that resulted in lipid mixing, subsequent
probe dequenching, and fluorescence increase. This approach was used to compare the
fusogenic activity of the purified CHR mutants with that of WT P/rds. We found that fusogenic
activity required both conserved charged residues in the CHR. Nearly complete inhibition
resulted when single charges were neutralized at Glu321, Lys324, or both simultaneously. The
net charge change (relative to the WT sequence) for these three variants is +1, -1, and 0,
respectively, yet they impacted activity in an almost equivalent fashion. Thus, a simple
relationship between fusogenicity, as measured by lipid mixing, and net charge change is not
supported by these data. Instead, we found that any alteration of charge at these two positions
largely abrogated the ability to promote model membrane fusion.
Membrane Destabilization of CHR Mutants Expressed as GST Fusion Proteins in E. coli—
Although the mechanism(s) by which the CHR promotes model membrane fusion is not
understood, current evidence suggests that it involves binding and destabilization of
phospholipid membranes (24,25). Given that each of the CHR mutants we examined inhibited
fusogenic activity, a vesicle depolarization assay was adopted to investigate whether any of
these mutations acts by preventing membrane destabilization.
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Purified GST-C-terminal domain fusion proteins were assayed for their ability to induce SUV
leakiness as measured by membrane potential collapse. Fig. 7B shows the fluorescence
intensity increase of the potentiometric dye diS-C3-(5) due to SUV membrane destabilization
upon addition of GST-WT. We compared the destabilization activity of the purified CHR
mutants relative to that of WT P/rds. As shown in Fig. 7B, we found that destabilization, like
fusogenic activity, was severely inhibited by neutralization of single charges at both positions
321 and 324. Surprisingly and in contrast to fusogenic activity, destabilization activity was
significantly enhanced when these two charges were neutralized simultaneously
(E321L,K324A). Overall, these data indicate that, like in vitro fusogenic activity, membrane
destabilization is not simply related to charge density and, furthermore, that multiple
mechanisms underlie the observed loss of fusogenicity.

3K. Boesze-Battaglia, L. M. Ritter, and A. F. X. Goldberg, unpublished data.
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Early structure-function studies of P/rds focused upon the EC2 domain; this region includes
the majority of the hydrophilic protein sequence (∼150 amino acids) and is the site of both the
rds mouse defect and the originally described human disease-related mutations (13,16,34,49,
51-57). In contrast, the smaller 66-amino acid C terminus has to date been the subject of more
limited attention (17,20,24,25). Recent investigations, including this study, suggest that its
importance may previously have been overlooked. We used sequence analysis and engineered
missense mutations to investigate the role of conserved charged residues in the amphiphilic
CHR and found these sites are essential for fusogenic activity, but not biosynthesis, subunit
assembly, or OS localization. The fact that these properties can be uncoupled suggests that
inherited mutations in the C terminus might impair OS structure and photoreceptor viability
by specifically disabling membrane fusion.
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Several lines of evidence had led us to speculate previously that the C-terminal domain plays
a greater role in P/rds function than in protein structure (3). First, a transgenic mouse model
demonstrates that one or more domains in addition to EC2 are required for generating and
maintaining OS architecture (54). Second, P/rds subunit assembly and export from the
endoplasmic reticulum are both dependent upon determinants residing within the EC2 domain;
insertion mutations in the C terminus do not measurably affect these processes (22). Third,
reports of inherited genetic defects in humans and an engineered mutant mouse model both
show that retinal physiology can be adversely affected by an abnormal C terminus (13,59).
Finally, several studies have documented the ability of the C terminus to promote model
membrane fusion (17,24,25,60).
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This study was based in part on the presence of an amphipathic helix in the P/rds C terminus;
this feature was initially suggested by sequence analysis and later confirmed by a Fourier
transform IR study of a synthetic peptide (17,24). This region, Val312-Leu326 in the original
investigation, has been proposed to act as a fusion peptide, a sequence that, when triggered,
can insert into and promote fusion of apposed biological membranes. Fusion peptides required
for membrane fusion in viral entry are particularly well studied (26,61). Numerous mutagenesis
studies have demonstrated that alteration of fusion peptide sequence can strongly and
specifically affect the fusogenic activity of the larger fusion protein and indeed the entire
organism (as in a virus) (62-64). Similarly, a previous study of P/rds fusogenicity suggests that
its activity is strongly impacted by changes in the fusion peptide sequence (24). Most recently,
a recombinant version of the P/rds C terminus was shown to induce model membrane
destabilization and fusion (25). Since the P/rds homolog rom-1 does not display this activity,
we wondered whether differences in the CHR might contribute to the observed disparity in
fusogenic activity (28). Therefore, we replaced conserved charged residues in P/rds with
neutral residues from the aligned region of rom-1 (Fig. 1B). We reasoned that using a P/rds
homolog to guide our choice of neutralizing substitutions would provide the greatest likelihood
of maintaining normal protein structure. Secondary structure predictions indicated that helical
structure would be preserved for each of the CHR mutants.
In fact, none of the CHR mutants produced measurable effects on any aspect of protein
biosynthesis in COS-1 cells, including global folding, disulfide bonding, subcellular
localization, and tetrameric subunit assembly. These findings are consistent with previous
mutagenesis studies showing that gross protein structural properties, including folding,
disulfide formation, subunit assembly, and endoplasmic reticulum export, are dependent upon
determinants within the EC2 domain, but not the C terminus (22,32,43). Likewise, none of the
CHR mutations examined here measurably affected OS targeting and localization in transgenic
X. laevis photoreceptors. Given that the two charged residues targeted in this study reside within
a previously identified OS localization signal, it is note-worthy that substitutions at the
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conserved Glu321 and Lys324 residues do not disrupt targeting. The high degree of conservation
at these positions likely reflects their participation in other molecular activities. In addition,
the demonstration that these charged residues are not required for OS localization indicates
that their absence in the C terminus of the P/rds homolog rom-1 is not responsible for the lack
of targeting activity observed for that molecule (20). Given current knowledge, we consider
that multiple roles for the C terminus are likely and have proposed P/rds multifunctionality
previously (22). A more detailed investigation will be required to determine whether expression
of these mutant variants in transgenic X. laevis photoreceptors affects OS ultrastructure and
GFP localization at the ultrastructural level.
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In sharp contrast, all of the mutations reported here had dramatic consequences on P/rds
interaction with model membranes. Mechanisms of fusion peptide action are likely manifold
and are currently being debated; however, it is generally agreed that they function as oligomers
and must bind and destabilize membrane surfaces (26). All three mutations described here
strongly affected both membrane fusion, measured by lipid mixing, and membrane
destabilization, measured potentiometrically. Neutralization of either Glu321 or Lys324 largely
prevented model membrane fusion (Fig. 8). Since individual mutations at these positions also
severely inhibited destabilization, it is likely that these mutations impede membrane adhesion
and/or bilayer penetration. Additional studies are required to evaluate potential contributions
from each of these mechanisms. Interestingly, simultaneous neutralization of charged residues
in the double mutant also inhibited fusion, but significantly enhanced destabilization. Since
fusogenic activity requires peptide oligomerization, but destabilization does not, these results
suggest an inhibition of double mutant self-association at the membrane surface (66,67).
Although limited evidence suggests that the P/rds fusion peptide may oligomerize in aqueous
solution, its self-association state while bound to membranes is not known (24). The increased
destabilization produced by concurrent loss of Glu321 and Lys324 suggests that the double
mutant peptide may penetrate more deeply into the bilayer, akin to effects seen for neutralizing
mutations within the hemagglutinin fusion peptide (29,62,65). It is not apparent why the single
charge neutralization mutants do not also increase destabilization, and reconciling these
differences will require atomic level structural detail of the peptides in their membrane-bound
states. Overall, these findings demonstrate an uncoupling of fusogenic activity from other
protein properties and suggest the utility of using non-fusogenic P/rds to genetically
complement rds mice to test the hypothesis that fusogenic activity is important for
photoreceptor OS renewal.
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More than a dozen mutations in the P/rds C terminus have been associated with instances of
human retinal disease. Defects include missense, nonsense, splice, insertion, and deletion
mutations, and clinical phenotypes include autosomal dominant retinitis pigmentosa, cone
dystrophy, pattern dystrophy, adult vitelliform macular dystrophy, and butterfly-shaped
macular dystrophy (68-71). A mouse model for autosomal dominant retinitis pigmentosa that
possesses a Δ307 frameshift mutation leads to complete loss of the CHR and compromises
photoreceptor viability (59). Since a truncation of the CHR has previously been shown to inhibit
fusogenic activity (25), it is possible that fusogenic loss of function could contribute to the
Δ307 frameshift phenotype. This mutation generates a dominant-negative phenotype,
suggesting that the resulting gene product can inhibit WT protein function. Co-assembly (in
heterozygotes) of non-fusogenic P/rds with WT P/rds is likewise predicted to inhibit WT
protein function since C-terminal domain mutations do not impair subunit assembly (22).
Incorporation of even a single mutant polypeptide into an otherwise WT tetramer could affect
activity since fusion proteins are known to function as oligomers (26). This possibility remains
likely even if the Δ307 frameshift inactivates the OS localization signal since mutant
polypeptide assembly into WT protein-containing tetramers is predicted to effectively mask
localization signal defects. Furthermore, quality control mechanisms that prevent P/rds exit
from the biosynthetic pathway fail to distinguish mutant polypeptides that are assembled into
J Biol Chem. Author manuscript; available in PMC 2006 February 2.
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normal tetramers (58). Thus, a loss of fusogenic activity is predicted to result in a dominantnegative phenotype for individuals inheriting the Δ307 frameshift mutation. In the absence of
additional information, we do not exclude the possibility that the Δ307 frameshift mutation
may cause impaired targeting to the photoreceptor OS, disruption of OS protein-protein
interactions, and/or deleterious new interactions generated by the novel protein sequence
resulting from the frameshift.
We have addressed the importance of conserved charged residues located within the P/rds CHR
and found they are critical for interactions with model membranes, but not protein biosynthesis
or OS localization. The findings lead us to conclude that determinants for OS localization and
fusogenic activity are overlapping yet distinct. This conclusion reinforces our notion that a
multiplicity of molecular pathologies may contribute to the phenotypic heterogeneity
characteristic of P/rds-associated diseases and suggests that a dominant-negative phenotype
associated with a Δ307 frameshift mutation may result from an uncoupling of fusogenic
activity. Determination of whether OS renewal can be restored in rds mice by transgenic
complementation with non-fusogenic yet otherwise normal P/rds will be facilitated by the
findings described here and will provide additional insights into P/rds action within the
vertebrate photoreceptor.
Acknowledgements

NIH-PA Author Manuscript

Acknowledgments—We thank Drs. John Saari and Krzysztof Palczewski for the generous gift of the mAb C6
hybridoma line and Dr. Judith White for helpful discussions and critical review.

REFERENCES

NIH-PA Author Manuscript

1. Young RW. Investig. Ophthalmol. Vis. Sci 1976;15:700–725. [PubMed: 986765]
2. Nguyen-Legros J, Hicks D. Int. Rev. Cytol 2000;196:245–313. [PubMed: 10730217]
3. Boesze-Battaglia K, Goldberg AF. Int. Rev. Cytol 2002;217:183–225. [PubMed: 12019563]
4. Van Nie R, Ivanyi D, Demant P. Tissue Antigens 1978;12:106–108. [PubMed: 705766]
5. Demant P, Ivanyi D, Van Nie R. Tissue Antigens 1979;13:53–55. [PubMed: 419532]
6. Travis GH, Brennan MB, Danielson PE, Kozak CA, Sutcliffe JG. Nature 1989;338:70–73. [PubMed:
2918924]
7. Sanyal S, Jansen HG. Neurosci. Lett 1981;21:23–26. [PubMed: 7207866]
8. Hawkins RK, Jansen HG, Sanyal S. Exp. Eye Res 1985;41:701–720. [PubMed: 3830736]
9. Sanyal S, De Ruiter A, Hawkins RK. J. Comp. Neurol 1980;194:193–207. [PubMed: 7440795]
10. Chang GQ, Hao Y, Wong F. Neuron 1993;11:595–605. [PubMed: 8398150]
11. Arikawa K, Molday LL, Molday RS, Williams DS. J. Cell Biol 1992;116:659–667. [PubMed:
1730772]
12. Kedzierski W, Moghrabi WN, Allen AC, Jablonski-Stiemke MM, Azarian SM, Bok D, Travis GH.
J. Cell Sci 1996;109:2551–2560. [PubMed: 8923216]
13. Kohl S, Giddings I, Besch D, Apfelstedt-Sylla E, Zrenner E, Wissinger B. Acta Anat 1998;162:75–
84. [PubMed: 9831753]
14. Travis GH, Sutcliffe JG, Bok D. Neuron 1991;6:61–70. [PubMed: 1986774]
15. Molday RS, Hicks D, Molday L. Investig. Ophthalmol. Vis. Sci 1987;28:50–61. [PubMed: 2433249]
16. Wrigley JD, Ahmed T, Nevett CL, Findlay JB. J. Biol. Chem 2000;275:13191–13194. [PubMed:
10747861]
17. Boesze-Battaglia K, Lamba OP, Napoli AA Jr. Sinha S, Guo Y. Biochemistry 1998;37:9477–9487.
[PubMed: 9649331]
18. Goldberg AFX, Molday RS. Biochemistry 1996;35:6144–6149. [PubMed: 8634257]
19. Poetsch A, Molday LL, Molday RS. J. Biol. Chem 2001;276:48009–48016. [PubMed: 11641407]
20. Tam BM, Moritz OL, Papermaster DS. Mol. Biol. Cell 2004;15:2027–2037. [PubMed: 14767063]

J Biol Chem. Author manuscript; available in PMC 2006 February 2.

Ritter et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

21. Clarke G, Goldberg AFX, Vidgen D, Collins L, Ploder L, Schwarz L, Molday LL, Rossant J, Szel A,
Molday RS, Birch DG, McInnes RR. Nat. Genet 2000;25:67–73. [PubMed: 10802659]
22. GoldbergAFXFalesLMHurleyJBKhattreeNJ. Biol. Chem20012764270042706AF. X. [PubMed:
11553636]
23. Boesze-Battaglia K, Kong F, Lamba OP, Stefano FP, Williams DS. Biochemistry 1997;36:6835–
6846. [PubMed: 9184167]
24. Boesze-Battaglia K, Stefano FP, Fenner M, Napoli AA Jr. Biochim. Biophys. Acta 2000;1463:343–
354. [PubMed: 10675512]
25. Boesze-Battaglia K, Goldberg AF, Dispoto J, Katragadda M, Cesarone G, Albert AD. Exp. Eye Res
2003;77:505–514. [PubMed: 12957149]
26. White JM. Science 1992;258:917–924. [PubMed: 1439803]
27. Epand RM. Biochim. Biophys. Acta 2003;1614:116–121. [PubMed: 12873772]
28. Boesze-Battaglia K, Gretzula C. Investig. Ophthalmol. Vis. Sci 2003;44:4259.
29. Korte T, Epand RF, Epand RM, Blumenthal R. Virology 2001;289:353–361. [PubMed: 11689057]
30. Connell GJ, Molday RS. Biochemistry 1990;29:4691–4698. [PubMed: 2372552]
31. Goldberg AFX, Moritz OL, Molday RS. Biochemistry 1995;34:14213–14219. [PubMed: 7578020]
32. Goldberg AFX, Loewen CJ, Molday RS. Biochemistry 1998;37:680–685. [PubMed: 9425091]
33. Tam BM, Moritz OL, Hurd LB, Papermaster DS. J. Cell Biol 2000;151:1369–1380. [PubMed:
11134067]
34. Goldberg AFX, Molday RS. Methods Enzymol 2000;316:671–687. [PubMed: 10800708]
35. Kroll KL, Amaya E. Development 1996;122:3173–3183. [PubMed: 8898230]
36. Moritz OL, Tam BM, Knox BE, Papermaster DS. Investig. Ophthalmol. Vis. Sci 1999;40:3276–3280.
[PubMed: 10586953]
37. Wu M, Gerhart J. Methods Cell Biol 1991;36:3–18. [PubMed: 1811140]
38. Moritz OL, Peck A, Tam BM. Gene (Amst.) 2002;298:173–182. [PubMed: 12426105]
39. Nieuwkoop, PD.; Faber, J. Normal Table of Xenopus Laevis (Daudin): A Systematical and
Chronological Survey of the Development from the Fertilized Egg Till the End of Metamorphosis.
Garland Publishing Inc.; New York: 1994.
40. Struck DK, Hoekstra D, Pagano RE. Biochemistry 1981;20:4093–4099. [PubMed: 7284312]
41. Mayer LD, Hope MJ, Cullis PR. Biochim. Biophys. Acta 1986;858:161–168. [PubMed: 3707960]
42. Boesze-Battaglia K. Methods Enzymol 2000;316:65–86. [PubMed: 10800669]
43. Goldberg AFX, Molday RS. Proc. Natl. Acad. Sci. U. S. A 1996;93:13726–13730. [PubMed:
8943002]
44. Kneller DG, Cohen FE, Langridge R. J. Mol. Biol 1990;214:171–182. [PubMed: 2370661]
45. Trujillo MJ, Martinez-Gimeno M, Gimenez A, Lorda I, Bueno J, Garcia-Sandoval B, Ramos C,
Carballo M, Ayuso C. Hum. Mutat 2001;17:80. [PubMed: 11139263]
46. Zhang K, Garibaldi DC, Li Y, Green WR, Zack DJ. Arch. Ophthalmol 2002;120:485–490. [PubMed:
11934323]
47. Saga M, Mashima Y, Akeo K, Oguchi Y, Kudoh J, Shimizu N. Hum. Genet 1993;92:519–521.
[PubMed: 8244346]
48. Souied EH, Rozet JM, Gerber S, Dufier JL, Soubrane G, Coscas G, Munnich A, Kaplan J. Eur. J.
Ophthalmol 1998;8:98–101. [PubMed: 9673478]
49. Loewen CJ, Moritz OL, Molday RS. J. Biol. Chem 2001;276:22388–22396. [PubMed: 11297544]
50. Loewen CJ, Molday RS. J. Biol. Chem 2000;275:5370–5378. [PubMed: 10681511]
51. Kedzierski W, Lloyd M, Birch DG, Bok D, Travis GH. Investig. Ophthalmol. Vis. Sci 1997;38:498–
509. [PubMed: 9040483]
52. Dryja TP, Hahn LB, Kajiwara K, Berson EL. Investig. Ophthalmol. Vis. Sci 1997;38:1972–1982.
[PubMed: 9331261]
53. Kedzierski W, Bok D, Travis GH. J. Neurochem 1999;72:430–438. [PubMed: 9886097]
54. Kedzierski W, Weng J, Travis GH. J. Biol. Chem 1999;274:29181–29187. [PubMed: 10506174]

J Biol Chem. Author manuscript; available in PMC 2006 February 2.

Ritter et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

55. Kedzierski W, Nusinowitz S, Birch D, Clarke G, McInnes RR, Bok D, Travis GH. Proc. Natl. Acad.
Sci. U. S. A 2001;98:7718–7723. [PubMed: 11427722]
56. Farrar GJ, Kenna P, Jordan SA, Kumar-Singh R, Humphries MM, Sharp EM, Sheils DM, Humphries
P. Nature 1991;354:478–480. [PubMed: 1749427]
57. Kajiwara K, Hahn LB, Mukai S, Travis GH, Berson EL, Dryja TP. Nature 1991;354:480–483.
[PubMed: 1684223]
58. Loewen CJ, Moritz OL, Tam BM, Papermaster DS, Molday RS. Mol. Biol. Cell 2003;14:3400–3413.
[PubMed: 12925772]
59. McNally N, Kenna PF, Rancourt D, Ahmed T, Stitt A, Colledge WH, Lloyd DG, Palfi A, O’Neill B,
Humphries MM, Humphries P, Farrar GJ. Hum. Mol. Genet 2002;11:1005–1016. [PubMed:
11978760]
60. Boesze-Battaglia K, Stefano FP. Exp. Eye Res 2002;75:227–231. [PubMed: 12137768]
61. Tamm LK, Crane J, Kiessling V. Curr. Opin. Struct. Biol 2003;13:453–466. [PubMed: 12948775]
62. Steinhauer DA, Wharton SA, Skehel JJ, Wiley DC. J. Virol 1995;69:6643–6651. [PubMed: 7474073]
63. Qiao H, Armstrong RT, Melikyan GB, Cohen FS, White JM. Mol. Biol. Cell 1999;10:2759–2769.
[PubMed: 10436026]
64. Gething MJ, Doms RW, York D, White J. J. Cell Biol 1986;102:11–23. [PubMed: 3753607]
65. Han X, Bushweller JH, Cafiso DS, Tamm LK. Nat. Struct. Biol 2001;8:715–720. [PubMed:
11473264]
66. Skehel JJ, Wiley DC. Cell 1998;95:871–874. [PubMed: 9875840]
67. Lau WL, Ege DS, Lear JD, Hammer DA, DeGrado WF. Biophys. J 2004;86:272–284. [PubMed:
14695269]
68. Kohl S, Christ-Adler M, Apfelstedt-Sylla E, Kellner U, Eckstein A, Zrenner E, Wissinger B. J. Med.
Genet 1997;34:620–626. [PubMed: 9279751]
69. Gruning G, Millan JM, Meins M, Beneyto M, Caballero M, Apfelstedt-Sylla E, Bosch R, Zrenner E,
Prieto F, Gal A. Hum. Mutat 1994;3:321–323. [PubMed: 8019570]
70. Felbor U, Schilling H, Weber BH. Hum. Mutat 1997;10:301–309. [PubMed: 9338584]
71. Grover S, Fishman GA, Stone EM. Ophthalmology 2002;109:1110–1117. [PubMed: 12045052]

NIH-PA Author Manuscript
J Biol Chem. Author manuscript; available in PMC 2006 February 2.

Ritter et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig.1.

A, domain organization of P/rds. Four transmembrane domains (TM1-4) and the presence of
several cysteine-containing motifs (not shown) in EC2 indicate a relationship within the
tetraspanin family of proteins. CTER, C-terminal domain. B, alignment of the P/rds and rom-1
sequences for the predicted CHR at positions 312-328 within the 66-amino acid C-terminal
domain. Conserved charged residues with three- to four-residue spacing are evident for P/rds.
This study investigated the importance of the conserved charges at positions 321 and 324 for
protein structure, localization, and fusogenic activity. Substitutions were guided by the aligned
rom-1 sequences. The 15-amino acid bovine (Bov) P/rds region previously implicated as a
fusion peptide is shaded. A recently reported localization signal (20) includes an additional
five amino acids upstream and eight amino acids downstream of the X. laevis (Xen) sequence
depicted. Mus, Mus musculus; Hum, human. C, mutant P/rds variants expressed as 1) full-
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length polytopic proteins in COS-1 cells for assay of protein biosynthesis, 2) C-terminal domain
fusions with GST in E. coli, and 3) C-terminal domain fusions with GFP modified with a
rhodopsin palmitoylation signal. This latter molecule acts as membrane-bound localization
reporter in X. laevis (33).
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Assay of CHR mutant expression and disulfide bonding in COS-1 cells by Western blot
analysis. COS-1 cells were transfected with plasmids encoding full-length mutant P/rds
variants: single mutants E321L and K324A and double mutant E321L,K324A. Transfected
COS-1 cell membranes were treated with N-ethylmaleimide to block free thiols and then
solubilized in denaturing SDS gel loading buffer. Samples were subjected to reducing (with
β-mercaptoethanol (+ β-ME)) or nonreducing (- β-ME) SDS-PAGE (10% resolving gels) and
then electroblotted onto Immobilon-P membrane and probed with anti-P/rds mAb C6. All CHR
mutants expressed robustly; moreover, each showed the ability to form disulfide-linked dimers,
akin to WT P/rds.
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Fig.3.

Subcellular localization of CHR mutants by indirect immunofluorescence microscopy.
A, characteristic endoplasmic reticulum (anti-calnexin antibody), Golgi (anti-KDEL receptor
antibody), and misfolded P/rds (anti-P/rds mAb C6, green) localization patterns are presented
for reference. Misfolding of P/rds variant IM7b has been reported previously (22). B, COS-1
cells transiently transfected with WT P/rds or the indicated mutant expression vectors were
fixed with paraformaldehyde, permeabilized with Triton X-100, and labeled with anti-P/rds
mAb C6 (red) and 4′,6-diamidino-2-phenylindole nuclear stain (blue). All CHR mutants
displayed mainly perinuclear distributions characteristic of localization within the Golgi
apparatus, akin to WT P/rds.
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Fig.4.

Subunit assembly assay of full-length CHR mutants by velocity sedimentation. Detergent
extracts from transiently transfected COS-1 cell cultures were sedimented under reducing
conditions in 5-20% (w/w) sucrose gradients. Fractionated gradients (and particulate fractions
(P)) were assayed for P/rds by Western blot analysis with mAb C6. Representative
chemiluminescent blots and corresponding plots generated by image analysis are shown for
WT P/rds, a previously characterized dimeric insertion mutant (IM10), and the three mutant
CHR variants. Immunoreactivity in sucrose gradient fractions was calculated as a percentage
of the total (soluble and particulate immunoreactivity); in all cases, the majority of the P/rds
reactivity remained in the soluble (versus particulate) fraction. As reported previously (22),
WT P/rds sediments as a single major peak characteristic of a tetrameric stoichiometry, but
IM10 displays a subunit assembly defect. All of the CHR mutants sedimented like the WT
protein, indicating that each is tetrameric and that subunit assembly is unaffected by charge
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neutralizations in the CHR. Sedimentation coefficient estimates for all variants were calculated
as described under “Experimental Procedures” and are reported in Table II.
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Localization of GFP-P/rds C-terminal domain fusion protein variants expressed in
transgenic X. laevis rod photoreceptors. Confocal microscopy was performed on
cryosections from stage 48-62 transgenic tadpole eyes expressing membrane-associated GFP
fusions with WT P/rds (A), E321L (B), and E321L,K324A (C). GFP fusion proteins (green)
were found almost exclusively in the outer segments (OS), with minimal localization observed
elsewhere (arrowheads). Thus, neutralization of CHR charged residues at positions 321 and
324 does not disrupt the normal localization of P/rds to the OS. Shown in D is a section from
a control eye showing OS localization driven by GFP-rhoCT44, which contains a rhodopsin
OS localization signal (33). Shown in E is a section from a control eye showing an example
of delocalization displayed by GFP-rhoCT44del5, which lacks an OS localization signal (33).
In addition to OS localization, abundant GFP fluorescence was observed in the lateral plasma
membranes and internal membranes of inner segments (IS) as well as outer plexiform layer
(OPL) membranes (arrowheads). Shown in F is a section from a control eye in which no GFP
was expressed. Red indicates Texas Red-conjugated wheat germ agglutinin, and blue indicates
Hoechst 33342. Bar = 20 μm.
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Expression and purification of GST-P/rds C-terminal domain fusion proteins. The Cterminal domain for each variant was expressed as a GST fusion protein in E. coli by induction
with isopropyl-1-thio-β-D-galactopyranoside. Purification was performed using a glutathioneagarose affinity matrix, and eluted proteins (predicted masses of ∼28 kDa) are shown separated
by 15% SDS-PAGE and stained with Coomassie Blue. Each was routinely purified to >70%
purity; truncated products, including GST, constitute the majority of the remaining impurities.
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Membrane interactions of P/rds CHR mutants. A, assay of fusogenicity (lipid mixing) as
measured by FRET. Affinity-purified GST fusion proteins (8.3 μg/ml final concentration) were
added individually to LUVs containing the lipophilic fluorophores Rh-PE and NBD-PE in the
presence of additional unlabeled vesicles (10 μM phospholipid final concentration).
Neutralization of Glu321, Lys324, or both significantly impaired the ability of the P/rds C
terminus to mediate vesicle fusion. Error bars represent S.D. B, membrane destabilization by
GST-P/rds C-terminal domain fusion proteins. The potentiometric dye diS-C3-(5) was utilized
to measure the ability of the CHR variants to induce membrane leakiness in SUVs (42).
Membrane destabilization was inferred from the ability of the variants (10 μg/ml protein final
concentration) to collapse the membrane potential and to allow diS-C3-(5) fluorescence
recovery (25). Neutralization of either Glu321 or Lys324 abrogated the ability of the P/rds C
terminus to depolarize SUVs; in contrast, simultaneous neutralization of Glu321 and Lys324
significantly enhanced SUV depolarization.

J Biol Chem. Author manuscript; available in PMC 2006 February 2.

Ritter et al.

Page 25

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Fig.8.

Effects of neutralizing conserved CHR residues. Helical models of WT and mutant P/rds
sequences illustrate hydrophobic faces (shaded) and residues targeted in this study (boxed).
The consequences of the substitutions are indicated below each variant. Data are summarized
as follows: ++, enhanced; +, WT P/rds; -, inhibited; ND, not determined.
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Synthetic oligonucleotides used for targeted mutagenesis
Variant
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pGST-E321L
pGST-K324A
pGST-E321L,K324A

Oligonucleotides
5′ -CCTTTCTGCTGAGTGTGAAGAAGCTGGGCA-3′ (forward)
5′ -TGCCCAGCTTCTTCACACTCAGCAGAAAGG-3′ (reverse)
5′ -GGCCTTTCTGGAGAGTGTGGCGAAGCTGG-3′ (forward)
5′ -CCAGCTTCGCCACACTCTCCAGAAAGGCC-3′ (reverse)
5′ -CTGAGTGTGGCGAAGCTGGGCAAGGGCAAC-3′ (forward)
5′ -GTTGCCCTTGCCCAGCTTCGCCACACTCAG-3′ (reverse)
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Consequences of CHR mutations on subunit assembly and sedimentation coefficientsVelocity dsedimentation
coefficients (s20,w) for full-length mutant variants are given as means ± S.D. The number of independent
transfection/ sedimentation trials for each is given in parentheses. WT P/rds from detergent extracts of transfected
COS-1 cells sediments as a characteristic tetramer under reducing conditions in 5–20% (w/w) sucrose gradients
(31). None of the mutations assayed measurably affected P/rds subunit assembly.
P/rds
WT
E321L
K324A
E321L,K324A

s20,w
5.4 ± 0.2 (8)
5.3 ± 0.5 (4)
5.5 ± 0.2 (3)
5.4 ± 0.1 (3)
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